AstraZeneca slides after report of Bristol Myers merger talks leaves analysts 'perplexed'
📰 source: cnbc_topnews · 💼 business
astrazeneca shares dropped as much as 7% after the financial times reported on sunday that the u.k. drugmaker was in merger talks with u.s. peer bristol myers squibb. a combined company could be valued at roughly $400 billion, which would make it one of the biggest pharma deals ever. london-listed shares were last down 6%, while bristol myers rose 3.8% in u.s. premarket trading.
astrazeneca's market cap is $264 billion, versus $133 billion for bristol myers. jefferies analysts said they were 'perplexed' given astrazeneca's growth and innovation profile. 'if there is one company that doesn't need financial engineering, it's az,' they wrote. one rationale: astrazeneca wants closer ties to the u.s., where it made 42% of sales in the first half of 2026 and where it completed a direct nyse listing this year. bristol myers gets 69% of revenue from the u.s.
the combined oncology portfolio would likely be the industry's broadest, possibly drawing antitrust scrutiny. citi analysts called the report a 'surprise' given astrazeneca's best-in-class pipeline. astrazeneca declined to comment.
why it matters: potential $400b pharma mega-merger would reshape oncology and boost u.s. exposure for astrazeneca, a major strategic shift.
source: cnbc_topnews
sentiment: -0.50 · impact: 0.70